Context Therapeutics

Context acquired CT-95, a potentially first-in-class mesothelin (“MSLN”) x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. Learn more here. https://lnkd.in/gVu_g6zw

Context Therapeutics is growing! For those ready to apply, more information about careers at Context Therapeutics can be found at: https://lnkd.in/dgg9-MU

Thank you to BiotechTV and Ali Gorman for sharing the Context Therapeutics story and highlighting the company's mission to advance therapeutics for solid tumors.

Today, we reported our first quarter 2024 operating and financial results as well as recent corporate highlights, including the completion of our $100 million private placement. https://lnkd.in/gCv-3WYS

Today, we announced that the U.S. Food and Drug Administration has cleared our Investigational New Drug (IND) application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a Phase 1 dose escalation and expansion #clinicaltrial of CTIM-76 in patients with CLDN6-positive #gynecologic and #testicular #cancers. Context anticipates the enrollment of the first patient in the dose escalation portion of its clinical trial in mid-2024. https://lnkd.in/g9FkTBNP

Today, we announced a $100 million private placement. This financing, together with Context's existing cash and cash equivalents, is expected to extend our cash runway into 2028. https://lnkd.in/gsixD9Cs

Today, we announced Context submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76, a potentially best-in-class Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers.  https://lnkd.in/euZCVGfW

Today, we reported our full year 2023 operating and financial results as well as recent corporate highlights. https://lnkd.in/eixicBSv

Happy Thanksgiving from all of us at Context! We are grateful for our network of colleagues and partners who help us with our mission to advance medicines for solid tumors to improve #cancertreatment. Best wishes to all for a safe, relaxing day with family and friends. 🦃 

#DYK: November is #LungCancerAwarenessMonth? According to the American Cancer Society, 238,340 new cases of #lungcancer will be diagnosed this year. At Context, we're developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody, to potentially treat CLDN-6 positive tumors including non-small cell lung cancer.